Broadly neutralising antibody plus cabotegravir maintains viral suppression for at least a year
Long-acting HIV treatment maintained viral suppression in 94% of patients, with just 1% experiencing virologic failure. Read more.
2 sourcesUpdated 1m ago

Coverage across the spectrum
How we rate outletsLeft 0% · 0Center 100% · 2Right 0% · 0
The story so far
- Long-Acting HIV Treatment Maintains 94% Viral Suppression: IDWeek 2026.
Summarised from the linked sources. Methodology
Who's reporting it
Reader Discussion
Loading comments…


/file/attachments/2999/14237139_154299.jpg)

